´ëÇÑÆó¾ÏÇÐȸ (¿Â¶óÀÎ) 2021 KALC International Conference (1ÀÏÂ÷) : 2021-11-25±³À°ÀÏÀÚ : 2021-11-25
±³À°Àå¼Ò : ¿Â¶óÀÎ Çмú´ëȸ
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) 2021 KALC International Conference (1ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
´ã´çÀÚ : ±èÀÎÁ¤
¿¬¶ôó : 02-741-8540
À̸ÞÀÏ :
kalc@lungca.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, °áÇÙ°ú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, ÇÙÀÇÇаú
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 8 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 70,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11-25 ¿Â¶óÀÎ 08:00~08:50 Cancer Evolution and How Early Intervention May Improve Chance of Cure Nicholas McGranahan(Univ. College London UK)
±³À°½Ã°£ 11-25 ¿Â¶óÀÎ 08:50~09:10 Liquid Biopsy, What Is the Best Approach? Pimpin Incharoen(Mahidol Univ. Thailand)
±³À°½Ã°£ 11-25 ¿Â¶óÀÎ 09:10~09:30 Molecular Biomarker Testing for Non-Small Cell Lung Cancer: Consensus Statement of the Korean Cardiopulmonary Pathology Study Group Sunhee Chang(Inje Univ)
±³À°½Ã°£ 11-25 ¿Â¶óÀÎ 09:30~09:50 The Era of Personalized Medicine: How the Pathologist Can Make a Difference? Philippe Joubert(Laval Univ. Canada)
ÈÞ½Ä 11-25 ¿Â¶óÀÎ 09:50~10:10 Coffee Break ()
±³À°½Ã°£ 11-25 ¿Â¶óÀÎ 10:10~10:35 How to Develop Credible, Useful Real-World Evidence Including Artificial Intelligence and Big Data Analytics Brain D. Bradbury(Center for Observational Research at Amgen USA)
±³À°½Ã°£ 11-25 ¿Â¶óÀÎ 10:35~11:00 Way of Real-World Evidence: Past, Present, and Future Opportunities in Korea Ju-Young Shin(Sungkyunkwan Univ.)
±³À°½Ã°£ 11-25 ¿Â¶óÀÎ 11:00~11:15 New Version of Tumor, Node, Metastasis (TNM) Staging Hisao Asamura(Keio Univ. Japan)
±³À°½Ã°£ 11-25 ¿Â¶óÀÎ 11:15~11:25 Domestic Lung Cancer Disease Investigation ProjectÅ×½ºÆ® Ho Cheol Kim(Univ. of Ulsan)
±³À°½Ã°£ 11-25 ¿Â¶óÀÎ 11:25~12:10 Recent Update of Checkmate 9LA and Checkmate 227, Pivotal Trials in 1L Non-Small Cell Lung Cancer Manuel Cobo Dols(Hospital Regional Universitario Málaga Spain)
½Ä»ç 11-25 ¿Â¶óÀÎ 12:10~13:00 Lunch Break ()
±³À°½Ã°£ 11-25 ¿Â¶óÀÎ 13:00~13:25 Targeting mEGFR with 3rd Generation TKI Se-Woong Oh(Yuhan Corporation)
±³À°½Ã°£ 11-25 ¿Â¶óÀÎ 13:25~13:50 Targeting KRAS David S. Hong(MD Anderson Cancer Center USA)
±³À°½Ã°£ 11-25 ¿Â¶óÀÎ 13:50~14:15 Targeting Fusion Driver Mutation Alice T. Shaw(Novartis USA)
±³À°½Ã°£ 11-25 ¿Â¶óÀÎ 14:15~14:40 Challenges in the Use of Targeted Therapy in Non-Small Cell Lung Cancer Alex A. Adjei(Mayo Clinic USA)
ÈÞ½Ä 11-25 ¿Â¶óÀÎ 14:40~15:00 Coffee Break ()
±³À°½Ã°£ 11-25 ¿Â¶óÀÎ 15:00~15:25 Subxiphoid Single Port VATS Thymectomy Sukki Cho(Seoul National Univ.)
±³À°½Ã°£ 11-25 ¿Â¶óÀÎ 15:25~15:50 Robotic Thymectomy Chang Hyun Kang(Seoul National Univ.)
±³À°½Ã°£ 11-25 ¿Â¶óÀÎ 15:50~16:15 Robotic Pulmonary Lobectomy Giulia Veronesi(Humanitas Research Hospital Italy)
±³À°½Ã°£ 11-25 ¿Â¶óÀÎ 16:15~16:40 Single Port Robotic Thoracic Surgery Seong Yong Park(Yonsei Univ)
ÈÞ½Ä 11-25 ¿Â¶óÀÎ 16:40~16:50 Coffee Break ()
±³À°½Ã°£ 11-25 ¿Â¶óÀÎ 16:50~17:40 The Role and the Current Status of Immunotherapy in Lung Cancer Treatment Michael Holmes(MSD UK)